Advertisement
Advertisement

SNDX

SNDX logo

Syndax Pharmaceuticals, Inc.

20.40
USD
Sponsored
+0.64
+3.24%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

20.30

-0.10
-0.47%

Syndax Pharmaceuticals, Inc. Profile

About

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Info & Links

CEO

Michael A. Metzger

Headquarters

730 Third Avenue, 9th Floor
New York, NY 10017, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.syndax.com

Auditor

Deloitte & Touche LLP

Share holders

11

Employees

298

Syndax Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization2

1.81B

Enterprise Value

2.06B

Enterprise Value/EBITDA(ttm)

-10.36

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

7.17

Price to Book(mrq)

119.72

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

95.75%

Operating Margin(ttm)

-87.52%

Profit Margin(ttm)

-91.32%

Return on Equity(ttm)

-372.94%

Return on Invested Capital(ttm)

-49.81%

Return on Assets(ttm)

-39.11%

Income Statement

Revenue(ttm)

252.00M

Revenue Per Share(ttm)

2.82

Gross Profit(ttm)

241.36M

EBITDA(ttm)3

-199.25M

Net Income Available to Common(ttm)

-220.76M

Diluted EPS(ttm)

-2.51

Share Statistics

Beta (5Y Monthly)

0.40

52-Week Change

60.38%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

89.30M

Dividend Yield

0.00%

Float4

84.36M

% Held by Insiders

4.80%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

554.27M

Total Cash Per Share(mrq)

6.21

Total Debt(mrq)

588.12M

Total Debt/Equity(mrq)

3895.07%

Current Ratio(mrq)

6.77%

Quick Ratio(mrq)

5.06%

Book Value Per Share(mrq)

0.17

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.91

Free Cash Flow(ytd)

-80.66M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement